The pathogenesis of cell death in Parkinson's diseaseJENNER, Peter; OLANOW, C. Warren.Neurology. 2006, Vol 66, Num 10, issn 0028-3878, S24-S36, SUP4Article

Selegiline : Current perspectives on issues related to neuroprotection and mortalityOLANOW, C. W.Neurology. 1996, Vol 47, Num 6, pp S210-S216, issn 0028-3878, SUP3Article

Levodopa-induced dyskinesiasOLANOW, C. Warren.Annals of neurology. 2000, Vol 47, Num 4, issn 0364-5134, 206 p., SUP1Serial Issue

A scientific rationale for protective therapy in Parkinson's diseaseOLANOW, C. W.Journal of neural transmission. 1993, Vol 91, Num 2-3, pp 161-180, issn 0300-9564Article

A radical hypothesis for neurodegenerationOLANOW, C. W.Trends in neurosciences (Regular edition). 1993, Vol 16, Num 11, pp 439-444, issn 0166-2236Article

Continuous dopaminergic stimulation in early and advanced Parkinson's diseaseSTOCCHI, Fabrizio; OLANOW, C. Warren.Neurology. 2004, Vol 62, Num 1, pp S56-S63, issn 0028-3878, SUP1Article

Rationale for considering that propargylamines might be neuroprotective in Parkinson's diseaseOLANOW, C. Warren.Neurology. 2006, Vol 66, Num 10, issn 0028-3878, S69-S79, SUP4Article

New approaches to neuroprotective therapy in Parkinson's diseaseOLANOW, C. Warren.Neurology. 2006, Vol 66, Num 10, issn 0028-3878, 105 p., SUP4Serial Issue

A 61-year-old man with Parkinson's diseaseOLANOW, C. W.JAMA, the journal of the American Medical Association. 1996, Vol 275, Num 9, pp 716-722, issn 0098-7484Article

Levodopa/Dopamine Replacement Strategies in Parkinson's Disease-Future DirectionsOLANOW, C. Warren.Movement disorders. 2008, Vol 23, issn 0885-3185, S613-S622, SUP3Article

MAO-B inhibitors in Parkinson's diseaseOLANOW, C. W.Advances in neurology. 1993, Vol 60, pp 666-671, issn 0091-3952Article

Issues in neuroprotection clinical trials in Parkinson's diseaseKIEBURTZ, Karl.Neurology. 2006, Vol 66, Num 10, issn 0028-3878, S50-S57, SUP4Article

The role of COMT inhibition in the treatment of Parkinson's diseasePOEWE, Werner.Neurology. 2004, Vol 62, Num 1, pp S31-S38, issn 0028-3878, SUP1Article

Avoidance of dyskinesia: Preclinical evidence for continuous dopaminergic stimulationJENNER, Peter.Neurology. 2004, Vol 62, Num 1, pp S47-S55, issn 0028-3878, SUP1Article

A new approach to late onset myasthenia gravisOLANOW, C. W; ROSES, A.Geriatrics. 1984, Vol 39, Num 1, pp 91-99, issn 0016-867XArticle

Dopamine-mediated gene regulation in models of Parkinson's disease. DiscussionGERFEN, C. R; BEDARD; LANGSTON et al.Annals of neurology. 2000, Vol 47, Num 4, pp S42-S52, issn 0364-5134, SUP1Article

Understanding cell death in Parkinson's diseaseJENNER, P; OLANOW, C. W.Annals of neurology. 1998, Vol 44, Num 3, pp S72-S84, issn 0364-5134, SUP1Conference Paper

Defining Disease-Modifying Therapies for PD— A Road Map for Moving ForwardOLANOW, C. Warren; KIEBURTZ, Karl.Movement disorders. 2010, Vol 25, Num 12, pp 1774-1779, issn 0885-3185, 6 p.Article

The need for neuroprotective therapies in Parkinson's disease : A clinical perspectivePOEWE, Werner.Neurology. 2006, Vol 66, Num 10, issn 0028-3878, S2-S9, SUP4Article

Tolcapone and hepatotoxic effectsOLANOW, C. W.Archives of neurology (Chicago). 2000, Vol 57, Num 2, pp 263-267, issn 0003-9942Article

Medical treatment of levodopa-induced dyskinesiasRASCOL, O.Annals of neurology. 2000, Vol 47, Num 4, pp S179-S188, issn 0364-5134, SUP1Article

Early therapy for Parkinson's diseaseOLANOW, C. W.European neurology. 1992, Vol 32, pp 30-35, issn 0014-3022, SUP1Conference Paper

Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms ?OLANOW, C. W; CALNE, D.Neurology. 1992, Vol 42, Num 4, pp 13-26, issn 0028-3878, SUP4Article

Neuroprotection in Parkinson's disease: Clinical trials. DiscussionSTOCCHI, Fabrizio; OLANOW, C. Warren.Annals of neurology. 2003, Vol 53, pp S87-S99, issn 0364-5134, SUP3Article

Nigrostriatal system plasticity in Parkinson's disease : Effect of dopaminergic denervation and treatment. DiscussionHIRSCH, E. C; BENABID; OLANOW et al.Annals of neurology. 2000, Vol 47, Num 4, pp S115-S121, issn 0364-5134, SUP1Article